Literature DB >> 28029925

Myasthenia Gravis.

Nils E Gilhus1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 28029925     DOI： 10.1056/NEJMra1602678

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  175 in total

1.  Myasthenia gravis.

Authors:  Pierre R Bourque; Ari Breiner
Journal:  CMAJ       Date:  2018-09-24       Impact factor: 8.262

Review 2.  Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.

Authors:  Grayson Beecher; Brendan Nicholas Putko; Amanda Nicole Wagner; Zaeem Azfer Siddiqi
Journal:  Drugs       Date:  2019-03       Impact factor: 9.546

3.  Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.

Authors:  James F Howard; Vera Bril; Ted M Burns; Renato Mantegazza; Malgorzata Bilinska; Andrzej Szczudlik; Said Beydoun; Francisco Javier Rodriguez De Rivera Garrido; Fredrik Piehl; Mariarosa Rottoli; Philip Van Damme; Tuan Vu; Amelia Evoli; Miriam Freimer; Tahseen Mozaffar; E Sally Ward; Torsten Dreier; Peter Ulrichts; Katrien Verschueren; Antonio Guglietta; Hans de Haard; Nicolas Leupin; Jan J G M Verschuuren
Journal:  Neurology       Date:  2019-05-22       Impact factor: 9.910

4.  Huntington's disease with comorbid myasthenia gravis: a case report.

Authors:  S Chatzikonstantinou; I Dagklis; D Kazis; E Karantali; S Bostantjopoulou
Journal:  Hippokratia       Date:  2019 Jan-Mar       Impact factor: 0.471

Review 5.  B cells in the pathophysiology of myasthenia gravis.

Authors:  John S Yi; Jeffrey T Guptill; Panos Stathopoulos; Richard J Nowak; Kevin C O'Connor
Journal:  Muscle Nerve       Date:  2017-09-30       Impact factor: 3.217

Review 6.  Diagnostics of myasthenic syndromes: detection of anti-AChR and anti-MuSK antibodies.

Authors:  Francesca Andreetta; Elena Rinaldi; Emanuela Bartoccioni; Anna Pia Riviera; Elena Bazzigaluppi; Raffella Fazio; Giovanni Deiana; Alessandro Pini; Maria Grazia Giudizi; Fulvio Baggi
Journal:  Neurol Sci       Date:  2017-10       Impact factor: 3.307

Review 7.  Cholinesterases and the fine line between poison and remedy.

Authors:  Carey N Pope; Stephen Brimijoin
Journal:  Biochem Pharmacol       Date:  2018-01-31       Impact factor: 5.858

8.  High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria.

Authors:  Raffi Topakian; Fritz Zimprich; Stephan Iglseder; Norbert Embacher; Michael Guger; Karl Stieglbauer; Dieter Langenscheidt; Jakob Rath; Stefan Quasthoff; Philipp Simschitz; Julia Wanschitz; David Windisch; Petra Müller; Dierk Oel; Günther Schustereder; Stefan Einsiedler; Christian Eggers; Wolfgang Löscher
Journal:  J Neurol       Date:  2019-01-16       Impact factor: 4.849

9.  [Clinical effect of tacrolimus in the treatment of myasthenia gravis in children].

Authors:  Jiu-Wei Li; Fang Fang; Xiao-Tun Ren; Wei-Hua Zhang; Xin-Ying Yang; Chang-Hong Ren; Shuai Gong; Jun-Lan Lyu; Xiao-Hui Wang; Xu Wang; Hu-Sheng Wu; Chang-Hong Ding
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2020-09

Review 10.  Myasthenia gravis and infectious disease.

Authors:  Nils Erik Gilhus; Fredrik Romi; Yu Hong; Geir Olve Skeie
Journal:  J Neurol       Date:  2018-01-25       Impact factor: 4.849
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.